Novavax President of R&D Dr. Gregory Glenn to Discuss the Development of COVID-19 Vaccines on Panel at 2020 BIO Digital

Rhea-AI Summary

Novavax, Inc. (NASDAQ: NVAX) announced that Gregory M. Glenn, M.D., President of Research and Development, will participate in a panel discussion on COVID-19 vaccines at the 2020 BIO Digital conference on June 9 at 11:30 a.m. EDT. The panel will explore the complexities of vaccine development and the importance of collaboration in bringing vaccines to market. Additionally, Novavax is advancing its NVX-CoV2373 vaccine candidate for COVID-19 with Phase 1 results expected in July 2020, alongside positive Phase 3 results for its NanoFlu vaccine targeting influenza.

Positive

• Gregory M. Glenn will speak at the 2020 BIO Digital conference on COVID-19 vaccine development, showcasing industry leadership.
• The NVX-CoV2373 vaccine candidate for COVID-19 is advancing to Phase 1 trials, with results anticipated in July 2020.
• NanoFlu met all primary objectives in its pivotal Phase 3 clinical trial, indicating strong potential.

Negative

• No negative aspects identified.

GAITHERSBURG, Md., June 08, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Gregory M. Glenn, M.D., President of Research and Development, will join other vaccine industry leaders for a panel discussion at 2020 BIO Digital. Taking place on Tuesday, June 9 at 11:30 a.m. EDT, the panel will discuss COVID-19 vaccines. The conversation will consider the complex path from lab to clinical trials, the impact of the evolving science on candidate development and consider how collaboration will bring life-saving vaccines to the world.

Details for the panel are as follows:

100%; border-collapse:collapse !important;">

11%; width:11%; min-width:11%;">Title:	1%; width:1%; min-width:1%;">	88%; width:88%; min-width:88%;">“Leveraging Platforms and Partnerships to Develop COVID-19 Vaccines in Record Time”
Date and Time:		Tuesday, June 9, 11:30 a.m. PDT
Moderator:		Mark McClellan, M.D., Director, Duke Margolis Center for Health Policy
Panelists:		Dr. Glenn Margaret Hamburg, M.D., Foreign Secretary, National Academy of Medicine Peter Marks, M.D., Ph.D., Director, Center for Biologics Evaluation and Research, United States Food and Drug Administration Paul Stoffels, M.D., Vice Chairman of the Executive Committee, Chief Scientific Officer, Johnson & Johnson

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax recently initiated development of NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19, with Phase 1 clinical trial results expected in July of 2020. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M™ adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Contacts:

Investors
Novavax, Inc.
Erika Trahan
ir@novavax.com
240-268-2022

Westwicke
John Woolford
john.woolford@westwicke.com
443-213-0506

Media
Brandzone/KOGS Communication
Edna Kaplan
kaplan@kogspr.com
617-974-8659

FAQ

When is Novavax's panel discussion on COVID-19 vaccines?

The panel discussion will take place on June 9, 2020, at 11:30 a.m. EDT during the 2020 BIO Digital conference.

What vaccine candidates is Novavax developing?

Novavax is developing NVX-CoV2373, a COVID-19 vaccine candidate, and NanoFlu, a quadrivalent influenza vaccine.

What are the expectations for NVX-CoV2373?

Phase 1 clinical trial results for NVX-CoV2373 are expected in July 2020.

Who will be moderating the panel discussion at the BIO Digital conference?

Mark McClellan, M.D., Director of the Duke Margolis Center for Health Policy, will moderate the panel.

What are the recent achievements of Novavax?

Novavax's NanoFlu vaccine met all primary objectives in its pivotal Phase 3 clinical trial.